Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250274) titled 'A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER' on Aug. 4.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Sakai Tetsuya
Condition:
extensive stage small cell lung cancer
Intervention:
ALPS12: intravenous infusion
obinutuzumab: intravenous infusion
Recruitment Status: Not Recruiting
Phase: 1
Date of First Enrollment: 01/09/2025
Target Sample Size: 122
Countries of Recruitment:
Hong Kong
Japan
Taiwan
Japan
Australia
Japan
To know more, visit https://j...